Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GSK, Pfizer and RSV
GSK, Pfizer RSV shots must warn about rare paralysis risk
Barré for every million doses given.
GSK and Pfizer's RSV vaccines to carry warnings of neurological disorder risk
GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare neurological disorder, the U.S. Food Drug Administration said on Tuesday.
RSV vaccines from Pfizer, GSK take another hit with new FDA warning mandate
The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning about the risk of developing Guillain-Barré syndrome (GBS), a rare neurological condition that can cause paralysis.
FDA adds warning to RSV shots from GSK, Pfizer
Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.
GSK, Pfizer RSV Shots Required to Carry Guillain-Barré Syndrome Warnings
A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s Arexvy and Pfizer’s Abrysvo, prompting the regulator to require adjustments to the vaccines’ labels.
FDA Adds Guillain-Barre Syndrome Warning to Two RSV Vaccines
Before the RSV vaccines were approved, the FDA flagged potential GBS risks with the vaccines. After approval, the CDC continued to monitor for GBS risk. FDA conducted a postmarket
Pharmalittle: We’re reading about FDA commish’s parting thoughts, a warning on RSV shots, and more
He also articulated a very specific doctrine about the role of an FDA commissioner, one that is limited in its power and leaves many controversial decisions to career government officials. Califf said he would not directly comment on any individual,
Pfizer And GSK's RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder
FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines, citing increased Guillain-Barré syndrome risk. Study estimates 7-9 excess GBS cases per million doses.
GSK, Pfizer RSV vaccines to carry warnings of GBS, Reuters reports
GSK (GSK) and Pfizer (PFE) vaccines for respiratory syncytial virus, or RSV, will carry warnings that they can increase the risk of developing
13m
Guillain-Barre Syndrome explained as 2 RSV vaccines flag neurological 'risk'
As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...
Verywell Health on MSN
10h
The 'Quad-Demic' Is Creeping Up This Winter. Here's How To Protect Yourself
The best way to protect yourself from the flu and COVID is to get vaccinated. This can reduce your chances of getting sick ...
20h
FDA Urges Guillain-Barré Syndrome Warning On Labels Of RSV Vaccines Abrysvo And Arexvy
The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Los Angeles wildfire updates
California fires: How to help
Court allows report release
SCOTUS rejects Trump’s bid
'Pizzagate' gunman killed
Teen arrested with a gun
Illinois passes Karina's Bill
Peacock president to exit
DOJ sues Pennsylvania city
La Nina finally arrives
Judge scraps Title IX rules
Grizzly bears stay protected
Ex-FBI informant gets 6 yrs
Appeals her disqualification
Clarifies Siri privacy stance
Oscar nominations delayed
Mortgage rate inches up
Freed after brief detention
Presidential palace attack
Settles opioid lawsuit
Sworn in as NH governor
Crime leader pleads guilty
Russian strike in Ukraine
Santos' sentencing delayed
Wycheck had CTE
EC fined for data breach
New Orleans hires Bratton
1.2M-year-old ice core
Bill to sanction ICC OK'd
Sues over ‘Rust' prosecution
Lebanon's new president
Related topics
GSK
GlaxoSmithKline
Guillain–Barré syndrome
Food and Drug Administration
Feedback